Table 4.
Characterization of optimized formulations and their controls (without articaine), regarding average diameters (Size), polydispersity (PDI), zeta potential (ZP), nanoparticles concentration (NC, nanoparticles/mL), encapsulation efficiency (%EE) and drug loading (DL, %).
| Formulation | Size (nm) |
PDI | ZP (mV) | NC (× 1013/mL) |
%EE | DL (%) |
|---|---|---|---|---|---|---|
| NLC-CP-A | 261.8 ± 3.8 | 0.178 ± 0.021 | − 36.8 ± 0.2 | 4.68 ± 0.27 | 73.3 ± 0.2 | 8.2 ± 0.1 |
| NLC-CP1 | 230.6 ± 2.5 | 0.099 ± 0.013 | − 31.1 ± 0.7 | 6.96 ± 0.14 | - | |
| NLC-CP2-A | 228.9 ± 0.3 | 0.133 ± 0.036 | − 37.9 ± 0.9 | 5.50 ± 0.40 | 74.0 ± 0.1 | 8.3 ± 0.1 |
| NLC-CP2 | 227.1 ± 2.3 | 0.184 ± 0.034 | − 26.9 ± 0.3 | 7.30 ± 0.17 | – | |
| NLC-CO1-A | 269.3 ± 0.4 | 0.198 ± 0.003 | − 42.8 ± 1.7 | 4.28 ± 0.76 | 75.8 ± 0.1 | 8.5 ± 0.1 |
| NLC-CO1 | 220.9 ± 0.1 | 0.131 ± 0.012 | − 33.0 ± 0.5 | 4.80 ± 0.52 | – | |
| NLC-CO2-A | 189.6 ± 1.9 | 0.140 ± 0.006 | − 40.8 ± 0.3 | 8.14 ± 0.71 | 78.4 ± 0.1 | 8.8 ± 0.1 |
| NLC-CO2 | 206.9 ± 1.0 | 0.161 ± 0.007 | − 23.7 ± 0.3 | 6.15 ± 0.81 | – | |
| NLC-OO1-A | 265.0 ± 3.4 | 0.197 ± 0.031 | − 47.5 ± 1.5 | 5.34 ± 0.80 | 72.2 ± 0.3 | 8.1 ± 0.1 |
| NLC-OO1 | 236.4 ± 0.5 | 0.163 ± 0.030 | − 31.5 ± 0.7 | 6.08 ± 0.70 | – | |
| NLC-OO2-A | 230.6 ± 1.9 | 0.125 ± 0.016 | − 43.0 ± 1.5 | 8.85 ± 0.13 | 74.9 ± 0.1 | 8.3 ± 0.1 |
| NLC-OO2 | 225.7 ± 0.6 | 0.205 ± 0.022 | − 26.5 ± 0.1 | 4.90 ± 0.21 | – |